
New Curaleaf Millcreek Dispensary Location Opens
Key Takeaways
- Curaleaf has expanded its retail footprint with a new dispensary in Erie, Pennsylvania, enhancing customer experience and accessibility.
- The new Curaleaf Millcreek location offers an improved in-store layout, streamlined ordering, and enhanced customer flow.
Curaleaf is opening a new cannabis dispensary called Curaleaf Millcreek in Erie, Pennsylvania.
In a recent press release,
The Curaleaf Millcreek location can be found at 4934 West Ridge Road, Erie, PA 16506. With the new facility, it offers consumers an “improved in-store layout, streamlined ordering process, and enhanced customer flow,” (1).
“Adding a second dispensary in Erie marks an important step in how we continue to evolve our retail footprint in Pennsylvania,” said Boris Jordan, Chairman and CEO of Curaleaf (1). “This new location allows us to deliver a more convenient, welcoming, and elevated experience for patients, while expanding access to our trusted brands and award-winning product innovation. We look forward to serving the Erie community and welcoming both new and returning customers to Curaleaf Millcreek.”
A grand opening for the new location will be held on Saturday, December 27, 2025. Those in attendance will be able to receive special promotions, gifts with their purchases, and take part in giveaways.
Curaleaf International and Jupiter Research LLC Announce EU Medical Device Certification
In a May 2025 press release,
The device will be labeled as a certifiedClass IIa medical device and meets the regulatory standards in Europe (2). The press release (2) mentioned that “A comprehensive technical file and full EU Declaration of Conformity were assessed and approved by a recognized EU Notified Body, validating the device's quality, safety, and clinical robustness.” It also detailed that the device contains a magnetic snap-in cartridge, as well as a power supply that is rechargeable.
With the certification from the EU, healthcare professionals will be able to recommend the device in European countries, Canada, regions throughout Australasia, and the UK (2). Additionally, the device will be able to be offered in various global markets once it has been commercialized.
Boris Jordan, Chairman and CEO of Curaleaf, said (2), “Achieving EU medical certification is more than a regulatory milestone—it's a signal that medical cannabis innovation is moving into the mainstream of global healthcare. We're proud to offer a device that meets the highest standards of safety and quality, and we look forward to supporting patients and healthcare providers across Europe and beyond with a new, accurate and discrete option for treatment.”
TILT's Chief Executive Officer Tim Conder, commented (2), “Partnering with Curaleaf International on this project has been a natural extension of our long-standing partnership in the US. By delivering industry-leading, user-friendly solutions, our collaboration exemplifies how technology can revolutionise healthcare. Achieving EU medical certification on IP developed by our subsidiary Jupiter Research, validates the robustness of our engineering and R&D functions and sets a new benchmark for the industry.”
References
- Curaleaf opens second Erie Dispensary in Millcreek, Pennsylvania
https://www.prnewswire.com/news-releases/curaleaf-opens-second-erie-dispensary-in-millcreek-pennsylvania-302649562.html (accessed Jan 2, 2026). - Colli, M. Curaleaf International and Jupiter Research Partnership obtain EU Medical Device Certification for first liquid inhalation device
https://www.cannabissciencetech.com/view/curaleaf-international-and-jupiter-research-partnership-obtain-eu-medical-device-certification-for-first-liquid-inhalation-device (accessed Jan 2, 2026).
Newsletter
Unlock the latest breakthroughs in cannabis science—subscribe now to get expert insights, research, and industry updates delivered to your inbox.




